ChemomAb identified a novel chemokine pathway that mediates inflammation and fibrosis and subsequently developed proprietary antibodies that target it.  Compelling data has been gathered on the efficacy of ChemomAb’s lead compound in models of nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC)  and systemic sclerosis.

CM-101 is the lead monoclonal anti-chemokine antibody that binds  a unique target that was found to be overexpressed in the sera and in diseased tissues from patients with inflammatory fibrotic disorders.